PHATHOM PHARMACEUTICAL

Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital

14 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

06 дек 2023 08:00:00 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

28 ноя 2023 08:00:28 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

09 ноя 2023 08:00:01 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

01 ноя 2023 17:00:26 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

30 окт 2023 08:00:38 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

25 окт 2023 08:01:03 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD

26 сен 2023 08:01:00 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

05 сен 2023 08:00:01 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

21 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Second Quarter 2023 Results

10 авг 2023 08:01:28 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD

12 июн 2023 08:01:00 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

09 июн 2023 16:01:22 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

01 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock

23 май 2023 19:41:15 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock

23 май 2023 16:01:12 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA

23 май 2023 16:00:40 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports First Quarter 2023 Results

10 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023

09 май 2023 08:00:15 Источник Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch

04 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire